ALBANY, N.Y.--(BUSINESS WIRE)-- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced presentations on NanoKnife^® System clinical experience were given at the Society of Surgical Oncology (SSO) 2012 conference that took place March 21-24, 2012, in Orlando, Fla.

An oral presentation titled, "Image Guided Irreversible Electroporation in Locally Advanced Pancreatic Cancer: Improved Overall Survival," was presented by Dr. Robert Martin, University Of Louisville, Department of Surgery, Division of Surgical Oncology, Louisville, Ky. Additional authors included Doctors David Hays and Whitney Goodwin, Baptist Health, Little Rock, Ark.; and Doctors Kellie McFarlin, Madhu Prasad and Vic Valanovich, Henry Ford Hospital, Detroit, Mich.

In connection with a registry administered by the University of Louisville, Department of Surgery, Division of Surgical Oncology, 44 patients underwent procedures with the NanoKnife System for unresectable pancreatic cancer from December 2009 to October 2010. Overall survival was evaluated and compared to 85 matched stage three patients treated with standard therapy defined as chemotherapy and radiation therapy alone.

The authors noted that ninety percent of the patients treated with the NanoKnife System had chemotherapy alone, or chemo-radiation therapy, for a median duration of five months before a procedure with the NanoKnife System. Seventy-three percent underwent chemotherapy or chemo-radiation after a procedure with the NanoKnife System. The 90-day mortality in patients who had procedures with the NanoKnife System was two percent. Comparing patients with NanoKnife System procedures to those receiving standard therapy, the authors reported a significant improvement in local progression-free survival, 14 versus six months. Improvement also was reported for distant progression-free survival, 15 versus nine months. Overall survival was 20 months versus 13 months.

A poster presentation, titled "The Successful Implementation of Irreversible Electroporation for Tissue Ablation in Primary and Secondary Tumors of the Liver and Pancreas," also was given. The authors are Doctors Gary Deutsch; H. Walden, Mansoor Beg, Charles Conte, James Sullivan and John Wang, North Shore University Hospital, Hofstra-NSLIJ School of Medicine, Manhasset, N.Y.

Abstracts for the presentations may be found via the following link and are listed as abstract 18 and P243 respectively:

http://www.surgonc.org/uploads/SSO_Annual_Cancer_Symposium_2012_Abstract_Supplement.pdf

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011, and AngioDynamics' Form 10-Q for the quarterly period ended November 30, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics provided grants in support of the studies referred to in this release.

Company Contact:
AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 x1608
jgersuk@AngioDynamics.com
or
Investor Relations Contacts:
EVC Group, Inc.
Greg Gin, 646-445-4801
ggin@evcgroup.com
Doug Sherk, 415-652-9100
dsherk@evcgroup.com
or
Media Contact:
EVC Group, Inc.
Chris Gale, 646-201-5431
cgale@evcgroup.com

Source: AngioDynamics, Inc.

News Provided by Acquire Media